Atai Beckley NV reports Q3 cash and securities of $114.6 million

Reuters11-12

Atai Beckley NV reports Q3 cash and securities of $114.6 million

Atai Beckley NV reported cash, cash equivalents, and short-term securities of $114.6 million as of September 30, 2025, up from $72.3 million at December 31, 2024. The $42.3 million increase was mainly due to $148.8 million in net proceeds from equity-related issuances and $3.9 million from the sale of equity holdings, partially offset by $55.2 million used in operations and $21.8 million for debt payoff. During the period, the company completed a public offering of common shares with gross proceeds of approximately $150 million and finalized its strategic combination with Beckley Psytech Limited, forming AtaiBeckley. The FDA granted Breakthrough Therapy designation to BPL-003 for treatment-resistant depression, and positive Phase 2a and 2b data were reported for BPL-003. Atai Life Sciences shareholders also ratified the move of AtaiBeckley's corporate domiciliation to the US, expected around yearend 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atai Beckley NV published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001140361-25-041546), on November 12, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2582375295?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-12 20:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582375295","market":"us","top_or_hot":-1,"title":"Atai Beckley NV reports Q3 cash and securities of $114.6 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Atai Beckley NV reports Q3 cash and securities of $114.6 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Atai Beckley NV reported cash, cash equivalents, and short-term securities of $114.6 million as of September 30, 2025, up from $72.3 million at December 31, 2024. The $42.3 million increase was mainly due to $148.8 million in net proceeds from equity-related issuances and $3.9 million from the sale of equity holdings, partially offset by $55.2 million used in operations and $21.8 million for debt payoff. During the period, the company completed a public offering of common shares with gross proceeds of approximately $150 million and finalized its strategic combination with Beckley Psytech Limited, forming AtaiBeckley. The FDA granted Breakthrough Therapy designation to BPL-003 for treatment-resistant depression, and positive Phase 2a and 2b data were reported for BPL-003. Atai Life Sciences shareholders also ratified the move of AtaiBeckley's corporate domiciliation to the US, expected around yearend 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atai Beckley NV published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001140361-25-041546), on November 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Atai Beckley NV reports Q3 cash and securities of $114.6 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAtai Beckley NV reports Q3 cash and securities of $114.6 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-12 20:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Atai Beckley NV reports Q3 cash and securities of $114.6 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Atai Beckley NV reported cash, cash equivalents, and short-term securities of $114.6 million as of September 30, 2025, up from $72.3 million at December 31, 2024. The $42.3 million increase was mainly due to $148.8 million in net proceeds from equity-related issuances and $3.9 million from the sale of equity holdings, partially offset by $55.2 million used in operations and $21.8 million for debt payoff. During the period, the company completed a public offering of common shares with gross proceeds of approximately $150 million and finalized its strategic combination with Beckley Psytech Limited, forming AtaiBeckley. The FDA granted Breakthrough Therapy designation to BPL-003 for treatment-resistant depression, and positive Phase 2a and 2b data were reported for BPL-003. Atai Life Sciences shareholders also ratified the move of AtaiBeckley's corporate domiciliation to the US, expected around yearend 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atai Beckley NV published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001140361-25-041546), on November 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4539","symbol_name":"次新股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDL3HcXr5:1","article_id":"2582375295","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582375295","pubTimestamp":1762950023,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Atai Beckley NV reported cash, cash equivalents, and short-term securities of $114.6 million as of September 30, 2025, up from $72.3 million at December 31, 2024. The $42.3 million increase was mainly due to $148.8 million in net proceeds from equity-related issuances and $3.9 million from the sale of equity holdings, partially offset by $55.2 million used in operations and $21.8 million for debt payoff. During the period, the company completed a public offering of common shares with gross proceeds of approximately $150 million and finalized its strategic combination with Beckley Psytech Limited, forming AtaiBeckley. The FDA granted Breakthrough Therapy designation to BPL-003 for treatment-resistant depression, and positive Phase 2a and 2b data were reported for BPL-003. Atai Life Sciences shareholders also ratified the move of AtaiBeckley's corporate domiciliation to the US, expected around yearend 2025.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4539":"次新股","BK4007":"制药","ATAI":"Atai Beckley Inc"},"translate_title":"Atai Beckley NV报告第三季度现金和证券为1.146亿美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ATAI":0.9},"content_text":"Atai Beckley NV reports Q3 cash and securities of $114.6 million\n    \n\n        Atai Beckley NV reported cash, cash equivalents, and short-term securities of $114.6 million as of September 30, 2025, up from $72.3 million at December 31, 2024. The $42.3 million increase was mainly due to $148.8 million in net proceeds from equity-related issuances and $3.9 million from the sale of equity holdings, partially offset by $55.2 million used in operations and $21.8 million for debt payoff. During the period, the company completed a public offering of common shares with gross proceeds of approximately $150 million and finalized its strategic combination with Beckley Psytech Limited, forming AtaiBeckley. The FDA granted Breakthrough Therapy designation to BPL-003 for treatment-resistant depression, and positive Phase 2a and 2b data were reported for BPL-003. Atai Life Sciences shareholders also ratified the move of AtaiBeckley's corporate domiciliation to the US, expected around yearend 2025.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atai Beckley NV published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001140361-25-041546), on November 12, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.10","shortVersion":"4.35.10","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2582375295","isCrawlerRequest":true}